Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. R
![PDF) The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis PDF) The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis](https://i1.rgstatic.net/publication/341622127_The_impact_of_donor_type_on_outcomes_and_cost_of_allogeneic_hematopoietic_cell_transplant_for_pediatric_leukemia_a_merged_CIBMTR_and_PHIS_analysis/links/5fea2fb9a6fdccdcb812dc3e/largepreview.png)
PDF) The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis
Antimicrobial prophylaxis in adults and children undergoing hematopoietic cell transplantation: 2021 Polish recommendations
![Cancers | Free Full-Text | Breast Radiotherapy-Related Cardiotoxicity. When, How, Why. Risk Prevention and Control Strategies Cancers | Free Full-Text | Breast Radiotherapy-Related Cardiotoxicity. When, How, Why. Risk Prevention and Control Strategies](https://www.mdpi.com/cancers/cancers-13-01712/article_deploy/html/images/cancers-13-01712-g001.png)
Cancers | Free Full-Text | Breast Radiotherapy-Related Cardiotoxicity. When, How, Why. Risk Prevention and Control Strategies
Diana Mainella - Corporate Head of Uro-Oncology, Strategy and Commercial Excellence - Recordati | LinkedIn
Teva Secures European Approval of Trisenox® for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia (APL) - Chemdiv
![Hematogenous Extramedullary Relapse in Multiple Myeloma – A Multicenter Retrospective Study in 127 Patients | Request PDF Hematogenous Extramedullary Relapse in Multiple Myeloma – A Multicenter Retrospective Study in 127 Patients | Request PDF](https://i1.rgstatic.net/publication/334653520_Hematogenous_Extramedullary_Relapse_in_Multiple_Myeloma_-_A_Multicenter_Retrospective_Study_in_127_Patients/links/619c9c8ed7d1af224b1a2622/largepreview.png)
Hematogenous Extramedullary Relapse in Multiple Myeloma – A Multicenter Retrospective Study in 127 Patients | Request PDF
1 | Page EHA-SWG Aging and Hematology Annual Report 2017 MAIN SECTIONS (NOTE: sections 1-4 will be used for publication on EHA w
Teva Receives Positive Opinion from European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) to Exten
Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells
![Teva Secures European Approval of Trisenox for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia » FINCHANNEL Teva Secures European Approval of Trisenox for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia » FINCHANNEL](https://finchannel.com/wp-content/uploads/2016/11/heallthandbeauty_021trisenox.jpg)